Reduced-dose fludarabine, cyclophosphamide, and rituximab (FCR-Lite) plus lenalidomide, followed by lenalidomide consolidation/maintenance, in previously untreated chronic lymphocytic leukemia

Eradication of bone marrow minimal residual disease may prompt early treatment discontinuation in CLL

(2014) P. Strati et al.   BLOOD

Long-term follow-up of a phase 2 trial of single agent lenalidomide in previously untreated patients with chronic lymphocytic leukaemia

(2014) Christine I. Chen et al.   BRITISH JOURNAL OF HAEMATOLOGY

Lenalidomide and Rituximab for the Initial Treatment of Patients With Chronic Lymphocytic Leukemia: A Multicenter Clinical-Translational Study From the Chronic Lymphocytic Leukemia Research Consortium

(2014) Danelle F. James et al.   JOURNAL OF CLINICAL ONCOLOGY

Chemoimmunotherapy with oral low-dose fludarabine, cyclophosphamide and rituximab (old-FCR) as treatment for elderly patients with chronic lymphocytic leukaemia

(2014) Alessandro Gozzetti et al.   LEUKEMIA RESEARCH

Lenalidomide induces long-lasting responses in elderly patients with chronic lymphocytic leukemia

(2013) P. Strati et al.   BLOOD

Long-term results of chemoimmunotherapy with low-dose fludarabine, cyclophosphamide and high-dose rituximab as initial treatment for patients with chronic lymphocytic leukemia

(2012) K. A. Foon et al.   BLOOD

Minimal Residual Disease Quantification Is an Independent Predictor of Progression-Free and Overall Survival in Chronic Lymphocytic Leukemia: A Multivariate Analysis From the Randomized GCLLSG CLL8 Trial

(2012) Sebastian Böttcher et al.   JOURNAL OF CLINICAL ONCOLOGY

Lenalidomide as initial therapy of elderly patients with chronic lymphocytic leukemia

(2011) X. C. Badoux et al.   BLOOD

U.S. Food and Drug Administration Approval: Rituximab in Combination with Fludarabine and Cyclophosphamide for the Treatment of Patients with Chronic Lymphocytic Leukemia

(2011) S. J. Casak et al.   ONCOLOGIST

Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial

(2010) M Hallek et al.   LANCET

Lenalidomide induces complete and partial remissions in patients with relapsed and refractory chronic lymphocytic leukemia

(2008) A. Ferrajoli et al.   BLOOD

Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines

(2008) M. Hallek et al.   BLOOD

Chemoimmunotherapy With Low-Dose Fludarabine and Cyclophosphamide and High Dose Rituximab in Previously Untreated Patients With Chronic Lymphocytic Leukemia

(2008) Kenneth A. Foon et al.   JOURNAL OF CLINICAL ONCOLOGY